Products derived from the black chokeberry, Aronia melanocarpa, are claimed to be benefi cial in disorders or diseases associated with oxidative stress. The claims are based on evidence from in vitro studies and animal experiments. The active principle -a mixture of procyanidins, anthocyanins and phenolic acids -constitutes one of the most potent natural antioxidants. A systematic review was carried out of the quality of the clinical trials on chokeberry products that had been published up to December 2009, and conventionally established criteria were used to assess the strength of the evidence for their clinical effectiveness. Thirteen studies were identifi ed. The quality of most of the trials and, correspondingly, the evidence of effectiveness for Aronia products is poor. Though laboratory and clinical data indicate that chokeberry products may well be useful as 'functional food' for disorders or diseases related to oxidative stress, these promising indications need to be confi rmed in more rigorous studies before putative therapeutic uses can be confi dently recommended for chokeberry products.
INTRODUCTION
The black chokeberry, Aronia melanocarpa (Family Rosaceae), is native to North America and Canada and was introduced into Europe about a century ago. Because of the astringent taste of the raw berries and their smell of bitter-almonds, pure Aronia products are not particularly popular, although they have been documented as a 'functional food' in Russia since the 1940s. Chokeberry juice has been used primarily for blending with other juices or in the preparation of syrups, jellies, teas, liqueurs, spirits and fruit wine. The interest in Aronia products has recently increased, not only because of the putative health-promoting effects of Aronia, but also because the plant is pest-resistant and easy to cultivate (http://opus.haw-hamburg.de/volltexte/2008/513/ pdf/med_y_210.pdf). Laboratory reports of potentially useful activities began to appear in the mid 1990s, and these have been accompanied since 2000 by a modest number of reports of its use in a variety of clinical settings.
Chokeberries have a greater content of phenolic constituents than most of the other black berries (Kahkönen et al., 2001 , Wu et al., 2004 . These comprise procyanidins, anthocyanins and phenolic acids, and the amounts refl ect antioxidative potency in laboratory testing (Zheng and Wang, 2003) . Procyanidins and some anthocyanins may also form complexes with free iron and copper, which catalyse free-radical reactions and contribute to the reduction in pro-oxidative activity seen with Aronia products (Hider et al., 2001) . Popular health claims for Aronia products are that they: (i) combat heart disease and other cardiovascular problems, (ii) mitigate hypertension, (iii) maintain a healthy urinary tract, (iv) fi ght against bacteria and viruses, (v) strengthen memory, (vi) aid digestion and (vii) help to decrease the amount of cholesterol carried as low density lipoproteins (LDL) (www.associatedcontent. com/article/870111/10_benefits_of_aronia_berry. html?cat=51). Additional claims by association have been made in diabetes and arthritis (www.doverpost. com/lifestyle/x124604982/Studies-show-aronia-berriesmay-be-full-of-health-benefi ts), as well as in cancer (http://hubpages.com/hub/aronia). These claims are primarily based on research with other black berry products or isolated anthocyanins (Zafra-Stone et al., 2007) or are transferred from in vitro and experimental studies with chokeberry preparations (Kulling and Rawel, 2008) .
The aim of this systematic review is to evaluate the current clinical evidence for effectiveness of chokeberry preparations.
METHODS
Several electronic databases were searched: Medline/ OVID, Silverplatter, and CENTRAL from 1950 up to December 2009, using some or all of the search terms, chokeberry, Aronia, Aronia melanocarpa, and searched by hand for publications not stored electronically (e.g.: theses, webpages). Two authors (CC and SC) extracted the data independently and evaluated the quality of the C. CHRUBASIK ET AL. studies and the strength of the evidence of clinical effectiveness using the same criteria as in previous reviews Gagnier et al., 2004; Chrubasik et al., 2006 Chrubasik et al., , 2007a Chrubasik et al., , 2007b Chrubasik et al., , 2008 Vlachojannis et al., 2009 Vlachojannis et al., , 2010a Vlachojannis et al., , 2010b .
Briefl y, the assessment of quality was based on 'yes' or 'no' answers to the following questions (to the extent that they were applicable in the context of each study): Was or were:
(i) patients included on the basis of specifi ed eligibility criteria; (ii) randomization appropriate; (iii) treatment allocation concealed; (iv) baseline values of the groups similar; (v) outcome measures and control interventions explicitly described; (vi) co-interventions comparable; (vii) outcome measures relevant; (viii) adverse events fully described; (ix) attrition of patients from the study (the 'dropouts') fully described; (x) sample size based on a priori power calculation; (xi) in the event of attrition of patients during the study, analysis by intention-to-treat; (xii) point estimates and measures of variability presented for the primary outcome measure; (xiii) studies undertaken over an appropriate timecourse to demonstrate the putative effect.
Clearly, for some studies, particularly simple observational studies, some of the questions are not applicable but the inability to supply a 'yes' answer is, in itself, a marker of 'absence of quality' in systematic reviews of this sort.
Disagreements between the assessors over these deliberately simplifi ed questions were few (arising mostly from lack of transparency in describing methods) and were resolved after discussion. Adding up the 'yes' answers applicable to each study gave it a Total Score (TS) out of a maximum of 13. The distribution of Total Scores for the studies in the review is one way to indicate the strength of evidence of effectiveness from a group of individual studies. Early in the history of the clinical investigation of a particular product, most of the studies will be 'exploratory' in that they determine the conditions, study design and sample size needed in planning to maximize the chances of demonstrating useful clinical effects in later 'confi rmatory' studies.
A conventional way of assessing evidence of clinical effectiveness from a more mature body of work is to defi ne the evidence as 'strong', 'medium' or 'weak', according to the following criteria: (i) 'strong' -pooling of data from at least two confi rmatory studies demonstrating a clinically relevant effect; (ii) 'moderate' -consistent fi ndings from one confi rmatory study with a clinically relevant effect, multiple exploratory studies of high internal validity, or both; (iii) poor -multiple exploratory studies of low internal validity or a single study of high internal validity.
RESULTS
Thirteen clinical trials were identifi ed. They have been assigned a number from 1 to 13 in chronological order, to facilitate reference between the tables and the text. Table 1 gives some characteristics of the publications in which the studies appeared, and the general setting. Nine papers/abstracts were in English and the remaining four in Polish. In eight papers (numbers 4, 5, 7-11, 13), the setting was either the 'metabolic syndrome (papers 7, 9, 11) -a constellation of features under the general headings: abdominal obesity, atherogenic dyslipidaemia, hypertension, insulin resistance, and prothrombotic and pro-infl ammatory state -or conditions presenting with a single or limited selection of those features (papers 4, 5, 8, 10, 13) . Three of the remaining fi ve studies (papers 1-3) investigated effects of Aronia in other conditions with increased oxidative stress, and the other two (papers 6 and 12) were of the effects of Aronia on the antioxidant capacity in healthy volunteers (Table 1) . Table 2 gives some indication of how the studies were carried out. Five studies (papers 5, 7, 10, 12, 13) had only one group, two being simple observational studies of the effects of giving an Aronia product (paper 5 and 7), and the rest incorporating a formal, single or double crossover, either to a placebo or no treatment (10, 12, 13). The remaining studies were comparisons between an 'Aronia' group (receiving an Aronia product) and either a 'Placebo' group (receiving a placebo) or a 'Control' group of patients receiving nothing (papers 3, 4, 6, 8, 9, 11) or healthy subjects receiving nothing (1, 2).
In seven studies (papers 1, 2, 5, 7-9, 11) the Aronia product was Aronox R , prepared from the berries, not by a solvent extraction, but by purifi cation on a chromatographic bed, drying and vaporization (annaskoc@ak.am. wroc.pl), and standardized in 100 mg tablets each containing 15 mg of anthocyanins. In the remaining papers, the Aronia product consisted of juices with varying anthocyanin contents (Table 1) . We tried unsuccessfully to contact Dr Naruszewicz by phone and email (marek. naruszewicz@wum.edu.pl), in an attempt to clarify how and why he appears to have used three 85 mg tablets of Aronox R per day as his study medication -although Aronox tablets contain a 100 mg dose of dried juice.
The duration of the studies ranged from 2 h to 3 months, with most lasting between 4 and 8 weeks. In almost all of the studies, there was a striking multiplicity in the measurements undertaken as potential outcome measures -indicating a strong 'exploratory' trust to those studies. The use of the Aronia product was associated, in every study, with a favourable change in at least one or more of the measurements that had been undertaken (Table 3) . Table 4 shows the responses to the questions by which the quality of each study was assessed. All scored at least four 'yeses', for questions (i), (v), (vii) and (xiii) but, although all outcomes were explicitly described and Men with oligospermia had higher oLDL levels than normal men; during Aronia intake oLDL levels were in the normal range 3
Signifi cantly higher CD4 and CD8 T cell counts in the Aronia group only 4
All measures had improved in the Aronia group only 5
Increase of glutathione peroxidase and catalase activities, and erythrocyte Zn; decrease of erythrocyte Pb, Al, Cu 6
All measures were signifi cantly lower in the Aronia group only 7
Platelet aggregation and all blood lipids except HDL cholesterol changed benefi cially during intake of Aronia 8
Blood pressure, all measures of oxidative stress, and the adhesion molecules all reduced in the Aronia group only 9
Decrease of all measures except HDL-chol, fG and UA in the Aronia group only 10
Decrease of all measures except UA, HDL-chol, fi brinogen, hs-CRP and vitamin E; increase in HDL subfraction HDL-2 during intake of Aronia 11
Signifi cant increase in SOD and GP activities in the Aronia group only 12
Increase of antioxidant capacity and inhibition of lipid peroxidation during intake of Aronia 13
Benefi cial effect on endothelial function and lipid metabolism during intake of Aronia (i) patients included on the basis of specifi ed eligibility criteria yes yes yes yes yes yes yes yes yes yes yes yes yes (ii) randomization appropriate nk nk nk no no yes no semi no no no yes no (iii) treatment allocation concealed nk nk no no no nk no nk no no no no no (iv) baseline values of the groups similar nk nk nk nk nk nk nk yes no yes no yes yes (v) outcome measures and control interventions explicitly described yes yes yes yes yes yes yes yes yes yes yes yes yes (vi) co-interventions comparable nk nk nk nk n/a yes nk yes no yes nk yes yes (vii) outcome measures relevant yes yes yes yes yes yes yes yes yes yes yes yes yes (viii) adverse events fully described nk nk nk nk nk nk nk nk nk nk nk yes nk (ix) attrition of patients from the study fully described nk nk nk nk nk nk nk yes nk nk nk nk nk (x) sample size based on a priori power calculation no no no no no no no no no no no no no (xi) in the event of attrition, analysis by intention-to-treat nk nk nk nk nk nk nk yes nk nk nk nk nk (xii) point estimates and measures of variability for the primary outcome measure no no no no no no no no no yes no yes yes (xiii) timing appropriate yes yes yes yes yes yes yes yes yes yes yes yes yes Total score (sum of 'yes' responses) 4 4 4 4 4 6 4 8 4 7 4 9 7 relevant to the condition under study, there is no transparency as to whether any single outcome had been pre-specifi ed for the purposes of hypothesis testing and a priori planning of sample size as would be required for a study to be considered 'confi rmatory' rather than 'exploratory' as defi ned in the Methods. Thus, although the collection of ten studies centring on the metabolic syndrome and aspects thereof produced generally consistent favourable results for the chosen Aronia product, the collection does not include even a single 'confi rmatory' study, so that the overall strength of evidence, in even this reasonably coherent body of work, must be classifi ed as 'poor' by the criteria outlined in the Methods section. Besides the lack of transparency over advance stipulation of a critical outcome measure, only one study (paper 12) gave any adequate account of adverse events and only one gave adequate account of attrition (paper 8, in which the attrition was zero!). Attrition needs to be considered in relation to whether the results should be analysed per protocol or by intention-to-treat). Nonetheless, an encouraging feature of Table 4 is the trend towards improved study quality over the 9 years for which the Aronia products have been studied.
DISCUSSION
Although the limited body of work up to December 2009 presents evidence of clinical effectiveness which must be classifi ed as 'poor' by conventional criteria, it is by no means unpromising. However, for the products to gain the acceptance that they may well deserve, a new generation of 'confi rmatory' studies needs to be planned and undertaken. The evidence from laboratory investigations (reviewed recently, for example, by (Kulling and Rawel, 2008) , as well as the clinical studies covered in this review provide potentially valuable pointers for the planning process. The laboratory investigations consist of product stability studies and studies in animal models and cell lines of various areas of potential benefi t and toxicity, and dose fi nding.
Product stability studies
The rate of degradation of anthocyanins is affected by the type of anthocyanidin, the amount of glycosylated sugar and the care taken to reduce contact with air (specifi cally oxygen) during preparation before packaging in bottles or cartons (Kaack and Austed, 1998) , and during storage (the degradation of total anthocyanins has been shown to be 22% faster in cartons, for example, than in glass bottles (Trost et al., 2008) . Vitamin C can reduce the oxidative degradation of the anthocyanins (Kaack and Austed, 1998) and the near black anthrocyanidin-containing juices are often presented as dilutions other fruit juice, e.g. lemon juice. The in vitro antioxidant activity of a lemon juice mixture was twice as high when pure lemon juice was enriched with 5% of Aronia concentrate (González-Molina et al., 2008) . Dilutions of Aronia juice in lemon juice have an attractive red colour that depends on a mixture of glycosylated and non-glycosylated anthocyanins (aglycones). The ranking order of individual non-glycosylated anthocyanins in a blueberry-Aronia nectar (from the most to least stable) was as follows: cyanindin > peonidin > petunidin > malvidin = delphinidin. For the glycosylated anthocyanins, the sugar with which the anthocyanidin is glycosylated makes a difference, degradation rate being least with glucose as the glycosylating sugar, intermediate with galactose and most with arabinose (Trost et al., 2008) . In dilutions of Aronia concentrate 2.5% and 5% in a lemon juice, the red colour was retained over 60 days despite a degradation of more than 90% in the antioxidative capacity supplied by the anthocyanidins -so colour is no guide to potential effectiveness (González-Molina et al., 2008) .
Temperature is important. Keeping Aronia juice concentrate for 8 h at 60°C resulted in a decrease of the polyphenol and anthocyanidin content by 22% and 35%, respectively, with an associated decrease in antioxidant activity of 56%. Thus the prolonged drying processes used in the manufacture of some Aronia berry products may be better avoided (Kasparaviciene and Briedis, 2003; Kähkönen et al., 2001) . Freeze-drying may be a better option -or, depending on the cost of the raw materials, it may be cheaper simply to increase the dose of a product such as Aronox R . Whatever may be the case, there seems to be some scope for increasing the content of the putative active principle in future Aronia products.
Laboratory studies indicating potential benefi ts of Aronia or anthocyanins
The earliest documented laboratory demonstration of a potentially useful action of Aronia was an antiinfl ammatory effect shown in 1994 by Borissova and co-workers. Aronia anthocyanins were more effective than rutin in suppressing infl ammation in the rat paw oedema test. More recently, a potent antiinfl ammatory effect of a proprietary extract of Aronia was demonstrated in endotoxin-induced uveitis in rats (Ohgami et al., 2005) . After 24 h, the number of infl ammatory cells, the protein concentrations, and the levels of NO, PGE2, and TNFalpha in aqueous humour from both eyes were dosedependently decreased. The antiinfl ammatory effect of 100 mg of Aronia extract was as strong as that of 10 mg of prednisolone and stronger than that of either anthocyanin or quercetin, another component of the extract, when given alone. The same extract also dose-dependently suppressed LPS-induced nitric oxide synthase and COX-2 protein expressions in a mouse macrophage cell line, indicating that it acts in pathways that involve several infl ammatory mediators (Ohgami et al., 2005) .
In 1995, Niedworok et al. described 'protection against damage from cyclophosphamide' and radiation disease (1995 theses quoted in Niedworok's review; bdb.trzcianka.com.pl/oferujemy/Aronox badania/ANG/Table I-25_eng.pdf).
Another early demonstration of potential benefi t was by Atanasova-Goranova et al. in 1997 . Their study in rats showed a hepatoprotective effect: Aronia nectar (fruit juice and pulp from the black chokeberry) inhibited nitrosamine production induced by aminopyrin and sodium nitrite in rats with a concomitant reduction in organic liver damage. Aronia juice also showed a hepatoprotective effect when given as a pre-treatment in a rat model of hepatotoxicity (Valcheva-Kuzmanova et al., 2004 . The juice prevented the carbon tetrachloride-induced increase in transaminase activities, and also the elevation of plasma and liver malondialdehyde.
Two studies revealed some antimutagenic potential of Aronia extract or its anthocyanin ingredients (Gasiorowski et al., 1997; Gasiorowski and Brokos, 2001 ). Rats treated with the colonic carcinogen 'azoxymethane' and fed a diet with Aronia extract (385 mg of anthocyanins and 1645 mg of total phenolics per g of diet) had fewer foci of aberrant colonic crypts and less proliferation of colonic cells, suggesting that anthocyanin-rich Aronia extracts may offer some protection against colonic cancer (Lala et al., 2006) . However, although force feeding of rats with 8 mL/kg of chokeberry juice for 28 days was apparently harmless, doing so in combination with the chemical carcinogen, N-nitrosodiethylamine, caused more toxicity and DNA damage than the carcinogen alone (Krajka-Kuźniak et al., 2009) .
Isolated anthocyanins from Aronia were also shown to reduce pancreatic swelling in rats with PAF-or ceruleine-induced pancreatitis, with a concomitant decrease in lipid peroxidation and adenosine deaminase activity (Jankowski et al., 2000) . Generally 'antidiabetic' effects have been shown in various models of diabetes and hyperlipidemia (mimicking the metabolic syndrome) in rats. Large doses of Aronia juice (10 or 20 mL/kg) given for 6 weeks signifi cantly reduced elevated plasma glucose and triglycerides in rats with streptozotocininduced diabetes and diet-induced hyperlipidemia (Valcheva-Kuzmanova et al., 2007b) . Given for only 30 days they reduced plasma total cholesterol, LDL-cholesterol and triglycerides (Valcheva-Kuzmanova et al., 2007a) . In a similar rat model of pancreatic dysfunction, benefi ts have been demonstrated from feeding for 4 weeks with 0.2% chokeberry extract (714 mg/g total polyphenols, 57% anthocyanin glycosides; Agropharm) (Jurgoń ski et al., 2008) . Matsumoto et al. (2004) demonstrated a gastro-protective effect of a methanol extract of Aronia (DER 1:10) that was as effective as that of quercetin and was caused by the red pigment fraction of the extract. In a rat model in which gastric ulcers were induced by indomethacin, a signifi cant reduction of the depth and severity of mucosal lesions was found when Aronia juice was given concomitantly with the indomethacin (ValchevaKuzmanova et al., 2005) . Isolated Aronia anthocyanins have also been shown in rats to mitigate the effects of poisoning by lead (Kowalczyk et al., 2002) and cadmium (Kowalczyk et al., 2003) . Several in vitro studies, one open study in chimpanzees and two exploratory studies in humans have suggested that an aqueous elderberry extract may have a place in the treatment of viral infections including the pandemic ones (Vlachojannis et al., 2010b) . Black chokeberries contain even more anthocyanins than do elderberries (Wu et al. 2004) , and an in vitro study has shown that Aronia juice inhibited the reproduction of Infl uenza virus in its initial stages. Thus, proprietary standardized Aronia products may possibly have some use as antiinfl uenza preparations. (http://www.antibiotikamonitor.at/34_03/34_03_1_04.htm).
Such an extraordinary multiplicity of effects claimed for Aronia has suggested to many researchers and practitioners that the Aronia products affect very basic cellular processes that are common to its many putative effects -namely effects that reduce the pathological generation of oxygen free radicals and/or promote scavenging of oxygen free radicals (Kulling and Rawel, 2008) .
Safety
The Polish company Agropharm in Lodz has some unpublished data showing that intragastric administration of up to 5 g/kg of Aronia anthocyanins was not associated with any toxic symptoms in mice. Likewise, giving 10 mg/kg of anthocyanins for 6 weeks was well tolerated and the internal organs did not show any histological changes (http://bdb.trzcianka.com.pl/oferujemy/Aronox%20badania/ANG/Table%20I-25_eng. pdf). Nonetheless, the observations of (Krajka-Kuźniak et al., 2009) indicate that some attention needs to be given to the possibility that Aronia products and related substances may act synergistically with other foodstuffs, medicines, poisons, chemotherapeutic agents, etc., that may be relevant in patients for whom in future Aronia products might otherwise be indicated.
Pointers to planning 'confi rmatory' clinical studies
Setting. The metabolic syndrome and related disorders seem to be a promising target population to be studied, in that the conditions are prevalent, and increasingly so. Finding suitable subjects to study will be relatively easy and any demonstrated benefi ts are likely to reduce, not only the morbidity and mortality of the conditions, but also their enormous fi nancial burden. The same might be said of endemic viral diseases such as infl uenza.
Dose. Doses do, of course, need to be tailored to the target populations to be investigated, but current empirical experience suggests that the daily dose of an Aronia product should contain 300-600 mg of anthocyanins -considerably more than in the clinical studies reviewed here (http://bdb.trzcianka.com.pl/ oferujemy/Aronox%20badania/ANG/Table%20I-25_ eng.pdf). If the doses used in animal studies are extrapolated to humans, the daily dose would correspond to an anthocyanin content of 1600-3000 mg contained in about 700-1400 mL juice per day (see below). Considerations of dose need to take into account considerations of how different Aronia products are manufactured and stored (see above -Product stability).
Adverse reactions. Considerations of dose also need to be tempered by considerations of possible adverse interactions with co-medications (see above), and for effects that may conceivably not have been studied fully in animals. Although no adverse events were reported in any of the clinical studies reviewed, squeezed Aronia juice may have mild diuretic and laxative effects from its potassium content and sorbitol-related laxative effects. Long-term use of Aronia preparations may conceivably cause anaemia because of the iron-chelating effect of anthocyanins. Like other polyphenol-containing products, Aronia juice or concentrate can also cause superfi cial staining of the teeth (Shellis et al., 2005) . As with almost any product containing molecules of suffi cient size, hypersensitivity may occur, albeit rarely.
It is, of course mandatory that, for any adverse reactions that occur during any studies, a full description is provided, and a formal consideration of the likelihood that it is causally related to the product being studied. If subjects fail to complete the study because of adverse effects or any other reason, consideration of the possible effects of that attrition must be allowed for by comparing intention-to-treat and per protocol analyses of the results.
Outcome measures. Those used in the clinical trials reviewed to be reliable and relevant to improved wellbeing, and primary outcome measures need to be prespecifi ed as the basis of hypothesis testing and sample size calculations (see above).
Duration. Short and medium term studies of biochemical and cytological measurements are needed as well as simple clinical measurements such as body weight and arterial blood pressure (as in Table 2 ) which are indications of potential benefi t on terms of risk reduction. Longer term studies are also required to determine whether the potential risk reduction is translatable into better clinical outcomes from disease, improved life expectancies and greater confi dence that the potential benefi ts are not offset by toxicity in the longer term (www.fda.gov/cder/guidance/index.htm, www.emea. europa.eu/pdfs/human/ich/030095en.pdf).
CONCLUSION
In conclusion, there is appreciable experimental evidence of the effectiveness of Aronia products in an extraordinary range of pathological conditions in which the underlying damage is probably mediated by uncontrolled oxidative processes. The current evidence of effectiveness in several clinical contexts is promising, but does not yet meet the accepted standards that would secure them an indisputable place in therapy. Fortunately, there are several promising avenues of investigation that may be pursued to remedy the present shortcomings.
We wish to announce the tragic and untimely death of Dr med Cosima Chrubasik on 26th March 2010, which deprived not only her family of a much-loved daughter, but also denied medical science the talents of a gifted young researcher. Her intelligent and tenacious curiosity in her chosen fi eld means that she will be greatly missed by those who knew Cosima and her work.
